Free Trial
→ Is SpaceX really worth 1.78 Trillion? (From InvestPub) (Ad)tc pixel Free AEON Stock Alerts

AEON Biopharma (AEON) Competitors

AEON Biopharma logo
$0.72 0.00 (-0.01%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$0.68 -0.04 (-5.17%)
As of 06/12/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AEON vs. XBIT, CYPH, CLNN, BYSI, and GANX

Should you buy AEON Biopharma stock or one of its competitors? MarketBeat compares AEON Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AEON Biopharma include XBiotech (XBIT), Cypherpunk Technologies (CYPH), Clene (CLNN), BeyondSpring (BYSI), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical products" industry.

How does AEON Biopharma compare to XBiotech?

XBiotech (NASDAQ:XBIT) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XBiotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, XBiotech had 3 more articles in the media than AEON Biopharma. MarketBeat recorded 3 mentions for XBiotech and 0 mentions for AEON Biopharma. XBiotech's average media sentiment score of 1.31 beat AEON Biopharma's score of 0.00 indicating that XBiotech is being referred to more favorably in the media.

Company Overall Sentiment
XBiotech Positive
AEON Biopharma Neutral

XBiotech has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 30.8% of XBiotech shares are owned by insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

XBiotech is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotechN/AN/A-$45.54M-$1.32N/A
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A

AEON Biopharma's return on equity of 0.00% beat XBiotech's return on equity.

Company Net Margins Return on Equity Return on Assets
XBiotechN/A -26.10% -25.06%
AEON Biopharma N/A N/A -994.63%

Summary

XBiotech beats AEON Biopharma on 7 of the 13 factors compared between the two stocks.

How does AEON Biopharma compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

AEON Biopharma's return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Cypherpunk TechnologiesN/A -48.33% -42.21%
AEON Biopharma N/A N/A -994.63%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cypherpunk Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Cypherpunk Technologies had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for Cypherpunk Technologies and 0 mentions for AEON Biopharma. Cypherpunk Technologies' average media sentiment score of 1.89 beat AEON Biopharma's score of 0.00 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Cypherpunk Technologies Very Positive
AEON Biopharma Neutral

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cypherpunk TechnologiesN/AN/A$4.82M-$0.02N/A
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by company insiders. Comparatively, 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cypherpunk Technologies has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Summary

AEON Biopharma beats Cypherpunk Technologies on 7 of the 13 factors compared between the two stocks.

How does AEON Biopharma compare to Clene?

Clene (NASDAQ:CLNN) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, Clene had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for Clene and 0 mentions for AEON Biopharma. Clene's average media sentiment score of 1.89 beat AEON Biopharma's score of 0.00 indicating that Clene is being referred to more favorably in the media.

Company Overall Sentiment
Clene Very Positive
AEON Biopharma Neutral

Clene has higher revenue and earnings than AEON Biopharma. Clene is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clene$200K373.18-$26.17M-$3.20N/A
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A

23.3% of Clene shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 28.3% of Clene shares are held by insiders. Comparatively, 9.4% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Clene presently has a consensus target price of $33.25, indicating a potential upside of 469.35%. Given Clene's higher possible upside, research analysts plainly believe Clene is more favorable than AEON Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clene
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00

Clene has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

AEON Biopharma has a net margin of 0.00% compared to Clene's net margin of -25,009.70%.

Company Net Margins Return on Equity Return on Assets
Clene-25,009.70% N/A -137.98%
AEON Biopharma N/A N/A -994.63%

Summary

Clene beats AEON Biopharma on 11 of the 15 factors compared between the two stocks.

How does AEON Biopharma compare to BeyondSpring?

AEON Biopharma (NASDAQ:AEON) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
BeyondSpring
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
AEON BiopharmaN/A N/A -994.63%
BeyondSpring N/A N/A -14.00%

AEON Biopharma has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

In the previous week, BeyondSpring had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for BeyondSpring and 0 mentions for AEON Biopharma. BeyondSpring's average media sentiment score of 1.87 beat AEON Biopharma's score of 0.00 indicating that BeyondSpring is being referred to more favorably in the news media.

Company Overall Sentiment
AEON Biopharma Neutral
BeyondSpring Very Positive

BeyondSpring has higher revenue and earnings than AEON Biopharma. BeyondSpring is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A
BeyondSpring$1.75M36.89-$1.01M-$0.14N/A

Summary

BeyondSpring beats AEON Biopharma on 8 of the 13 factors compared between the two stocks.

How does AEON Biopharma compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Gain Therapeutics has higher revenue and earnings than AEON Biopharma. Gain Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain Therapeutics$50K1,433.04-$20.16M-$0.58N/A
AEON BiopharmaN/AN/A-$36.63M-$5.00N/A

Gain Therapeutics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Gain Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 405.95%. Given Gain Therapeutics' higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than AEON Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00

AEON Biopharma's return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gain TherapeuticsN/A -201.44% -136.24%
AEON Biopharma N/A N/A -994.63%

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Gain Therapeutics had 3 more articles in the media than AEON Biopharma. MarketBeat recorded 3 mentions for Gain Therapeutics and 0 mentions for AEON Biopharma. Gain Therapeutics' average media sentiment score of 0.64 beat AEON Biopharma's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Gain Therapeutics Positive
AEON Biopharma Neutral

Summary

Gain Therapeutics beats AEON Biopharma on 8 of the 15 factors compared between the two stocks.

Get AEON Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AEON vs. The Competition

Export
MetricAEON BiopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$18.09M$979.54M$6.52B$12.05B
Dividend YieldN/A4.84%2.67%5.66%
P/E Ratio3.971.4524.0024.42
Price / SalesN/A120.49533.77123.88
Price / CashN/A20.0627.4837.92
Price / Book-0.177.8510.556.82
Net Income-$36.63M-$4.88M$3.57B$337.56M
7 Day Performance-2.01%0.64%0.59%1.16%
1 Month Performance-0.91%-0.16%1.55%3.16%
1 Year Performance-21.54%47.51%25.41%30.60%

AEON Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AEON
AEON Biopharma
0.8198 of 5 stars		$0.72
0.0%		N/A-21.5%$18.09MN/A3.975
XBIT
XBiotech
0.9484 of 5 stars		$2.37
flat		N/A-11.4%$72.26MN/AN/A100
CYPH
Cypherpunk Technologies
0.5921 of 5 stars		$0.68
-4.6%		N/A+58.6%$71.92MN/AN/A40
CLNN
Clene
3.9135 of 5 stars		$5.57
+4.5%		$33.25
+496.9%		+42.4%$71.19M$200KN/A100
BYSI
BeyondSpring
0.2187 of 5 stars		$1.72
+1.2%		N/A-43.7%$70.73M$1.75MN/A80

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AEON) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel